NRF2 AS A THERAPEUTIC TARGET IN ACUTE LEUCEMIA – IN VITRO STUDIES WITH OLTIPRAZ

EHA Library, Raquel Alves, 324036

DECIPHERING CLINICAL IMPLICATION OF DYSREGULATED SERUM MICRORNAS IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A RESULT OF COMPREHENSIVE MICRORNA PROFILING BY DEEP SEQUENCING

EHA Library, Harshini Sriram, 325716

THE CLINICAL UTILITY OF A PLASMA MIRNA SIGNATURE IN MULTIPLE MYELOMA BONE DISEASE

EHA Library, Aristea-Maria Papanota, 325717

METABOLIC ADAPTATIONS IN CARFILZOMIB-RESISTANT MULTIPLE MYELOMA CELLS - A PILOT STUDY

EHA Library, Dominik Dytfeld, 325718

SINGLE CELL MULTI-OMIC ANALYSIS AND IMMUNE CELL TYPE PROFILING OF MULTIPLE MYELOMA WITH T(4;14).

EHA Library, Sanjay de Mel, 325719

LONG-TERM FOLLOW-UP RESULTS OF A MULTICENTER FIRST-IN-HUMAN STUDY OF THE DUAL BCMA/CD19 TARGETED FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Juan Du, 325720

FINAL ANALYSIS OF THE PHASE 3 TOURMALINE-MM1 STUDY INVESTIGATING IXAZOMIB + LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD (PRD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS (PTS)

EHA Library, PAUL RICHARDSON, 325721

UPDATED CARTITUDE-1 RESULTS OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Saad Z. Usmani, 325722

FCRH5 TARGET EXPRESSION IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CEVOSTAMAB IN AN ONGOING PHASE I DOSE ESCALATION STUDY

EHA Library, Teiko Sumiyoshi, 325723

EFFECTS OF SELINEXOR ON PREVIOUSLY TREATED MULTIPLE MYELOMA (MM) WITH RAS-MUTATIONS

EHA Library, Christopher Walker, 325724

MODULATION OF SOLUBLE B-CELL MATURATION ANTIGEN LEVELS BY TECLISTAMAB AND TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Suzette Girgis, 325725

SUBGROUP ANALYSIS ON RESPONSE TO INDUCTION THERAPY WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYLEOMA

EHA Library, Elias K. Mai, 325726

DARATUMUMAB PLUS CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE INDUCTION THERAPY IN MULTIPLE MYELOMA FOLLOWED BY DARATUMUMAB MAINTENANCE: END-OF-STUDY RESULTS FROM LYRA

EHA Library, Robert M. Rifkin, 325727

ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—OPTIMAL DOSE AND UPDATED EFFICACY AND SAFETY RESULTS

EHA Library, Roman Hájek, 325728

TIME TO BEST RESPONSE CORRELATES WITH OUTCOME IN THE RANDOMIZED COMPARISON BETWEEN KRD AND KTD FOLLOWED BY K MAINTENANCE OR OBSERVATION (AGMT-MM02 TRIAL)

EHA Library, Heinz Ludwig, 325729

CILTACABTAGENE AUTOLEUCEL FOR TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA: ADJUSTED COMPARISON OF CARTITUDE-1 OUTCOMES VERSUS REAL WORLD CLINICAL PRACTICE OBSERVED IN GERMAN REGISTRY

EHA Library, Hartmut Goldschmidt, 325730

MELFLUFEN PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA EXPOSED AND/OR REFRACTORY TO PRIOR ALKYLATORS – A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES

EHA Library, Paula Rodríguez-Otero, 325731

EFFICACY AND SAFETY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE BASED ON REFRACTORY STATUS TO LENALIDOMIDE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE BOSTON STUDY

EHA Library, Xavier Leleu, 325732

SUBGROUP ANALYSIS: EFFICACY AND SAFETY OF ORAL PANOBINOSTAT IN COMBINATION WITH SC BORTEZOMIB AND ORAL DEXAMETHASONE IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS > 75 YEARS OF AGE

EHA Library, Fredrik Schjesvold, 325733

SURVIVAL AMONG OLDER PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA TREATED WITH SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (XVD) IN THE BOSTON STUDY

EHA Library, Thierry Facon, 325734

COMPARISON OF OUTCOMES WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-1 VERSUS STANDARD OF CARE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS IN CLINICAL TRIALS OF DARATUMUMAB

EHA Library, Katja Weisel, 325735

MATCHING ADJUSTED INDIRECT COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY

EHA Library, Katja Weisel, 325736

FIRST-LINE THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: FINAL RESULTS OF THE OBSERVATIONAL STUDY FIRST-NIS

EHA Library, Holger Nückel, 325737

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IKEMA SUBGROUP ANALYSIS

EHA Library, Thierry Facon, 325738

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: IKEMA SUBGROUP ANALYSIS

EHA Library, Ivan Spicka, 325739

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS KD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF TIME TO NEXT TREATMENT, TIME TO PROGRESSION, AND PROGRESSION-FREE SURVIVAL FOR NEXT THERAPY

EHA Library, Saad Z. Usmani, 325740

DEVELOPMENT OF ANTIBODY RESPONSE TO SARS-COV-2 FOLLOWING ASYMPTOMATIC INFECTION IN PATIENTS WITH PLASMA CELL DISORDERS ON IMMUNOMODULATORY THERAPY

EHA Library, Wei Yee Chan, 325741

CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PIVOTAL PHASE 2 KARMMA STUDY

EHA Library, Salomon Manier, 325742

REAL-WORLD DURATION OF TREATMENT (DOT) WITH LENALIDOMIDE-DEXAMETHASONE (RD)-BASED REGIMENS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): OUTCOMES FROM THE GLOBAL INSIGHT MM STUDY

EHA Library, Noemi Puig, 325743

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS: IKEMA SUBGROUP ANALYSIS

EHA Library, Meletios-Athanasios Dimopoulos, 325744

A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION

EHA Library, María-Victoria Mateos, 325745

POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SAFETY SUBANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

EHA Library, Katja Weisel, 325746

SURVIVAL AND OUTCOMES OF NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS STRATIFIED BY TRANSPLANT STATUS DIAGNOSED BETWEEN 2007-2018: REAL-WORLD ANALYSIS FROM THE CANADIAN MYELOMA RESEARCH GROUP DATABASE

EHA Library, Hira Mian, 325747

COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS CONVENTIONAL TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Luciano J. Costa, 325748

A MULTINATIONAL CHART REVIEW OF REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, K. Martin Kortüm, 325749

PULMONARY FUNCTION TESTS REVEAL UNRECOGNIZED LUNG DYSFUNCTION AND HAVE INDEPENDENT PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS

EHA Library, Despina Fotiou, 325750

EFFECTIVENESS AND SAFETY OF IXAZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) OUTSIDE OF A CLINICAL TRIAL: FINAL ANALYSIS OF THE ‘USE VIA EARLY ACCESS TO IXAZOMIB’ (UVEA IXA) STUDY

EHA Library, Heinz Ludwig, 325751

OVERVIEW AND EVOLUTION OF TREATMENT LINES IN MULTIPLE MYELOMA FROM 2014 TO 2018: A RETROSPECTIVE STUDY USING THE FRENCH NATIONAL CLAIM DATABASE (SNDS)

EHA Library, Aurore Perrot, 325752

EXOSOMAL CIRCRNA CACNG2 IS A NOVEL BIOMARKER FOR MM-RELATED CARDIAC DISEASES

EHA Library, Manya Yu, 325753

AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA: IMPROVEMENT IN IMMEDIATE RESULTS USING NON-CRYOPRESERVED STEM CELLS

EHA Library, Pilar Dutari, 325754

CLINICAL VALUE OF MINIMAL RESIDUAL DISEASE ASSESSED BY MULTIPARAMETER FLOW CYTOMETRY IN AMYLOID LIGHT CHAIN AMYLOIDOSIS

EHA Library, Juan Li, 325755

EPIDEMIOLOGY OF MULTIPLE MYELOMA: DATA FROM THE FRENCH NATIONAL HEALTH INSURANCE DATABASE (SNDS)

EHA Library, Cyrille Touzeau, 325756

Introduction

EHA Library, S Horwitz, 337277

Clinical Advances With Epigenetic Targets in T-Cell Lymphomas

EHA Library, S Horwitz, 337278

Q&A

EHA Library, S Horwitz, 337279

Summary and Panel Discussion

EHA Library, S Horwitz, 337280

Q&A

EHA Library, S Horwitz, 337281

Epigenetic Targets in T-Cell Lymphomas

EHA Library, J Fitzgibbon, 337282

Epigenetic Targets in B-Cell Lymphomas

EHA Library, J Fitzgibbon, 337283

Clinical Advances With Epigenetic Targets in B-Cell Lymphomas

EHA Library, C Sarkozy, 337284

DELVING DEEP INTO CLL

EHA Library, M Hallek, 337287

Panel discussion and concluding remarks

EHA Library, P Moreau, 337288

FRESH PERSPECTIVES ON ENDURING CONVERSATIONS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, P Moreau, 337289

Welcome and Introduction

EHA Library, X Leleu, 337295

CAR T cell therapy: Clinical and practical aspects

EHA Library, X Leleu, 337296

Discussion and Q&A

EHA Library, X Leleu, 337297

The importance of immune microenvironment in multiple myeloma and current treatment landscape

EHA Library, P Rodriguez Otero, 337298

Broad immune stimulation in myeloma: The role of cereblon modulators

EHA Library, P Richardson, 337299

Targeted immune stimulation in myeloma: Immuno- and cellular therapies

EHA Library, N Raje, 337300

THE CHANGING FACE OF AML INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, G Roboz, 337301

Introduction

EHA Library, MA Dimopoulos, 337302

Story of hope – Key decisions in relapse treatment

EHA Library, MA Dimopoulos, 337303

Panel discussion & concluding remarks

EHA Library, MA Dimopoulos, 337304

Set new goals – New momentum in first-line therapy

EHA Library, O Landgren, 337305

A bright future - Evaluation of emerging therapies

EHA Library, G Cook, 337306

THE EVOLVING TREATMENT PARADIGM IN MYELOFIBROSIS

EHA Library, J Garcia, 337307

Welcome and introduction

EHA Library, K Linton, 337308

Indolent NHL: current practices and new treatment paradigm

EHA Library, K Linton, 337309

Q&A and discussion

EHA Library, K Linton, 337310

Closing remarks

EHA Library, K Linton, 337311

Integrating cell therapies in the treatment of DLBCL

EHA Library, P Barba, 337312

Immuno-oncology agents in the treatment landscape of cHL

EHA Library, M André, 337313

CAR T cell therapy in CLL: latest achievements and perspectives

EHA Library, A Kittai, 337314

Welcome, Introductions Pre-Test

EHA Library, A Röth, 337315

The Role of Emerging Treatments and Management Approaches in Cold Agglutinin Disease

EHA Library, A Röth, 337316

Post-test and Q&A

EHA Library, A Röth, 337317

Methods to Facilitate Early and Accurate Diagnosis in Cold Agglutinin Disease

EHA Library, W Barcellini, 337318

The Burden of Cold Agglutinin Disease

EHA Library, C Broome, 337319

Pathophysiology of Cold Agglutinin Disease – Understanding the Complement System

EHA Library, S Berentsen, 337320

Frontline therapy of adult Ph-positive ALL

EHA Library, R Foà, 337321

Panel discussion: Beyond chemotherapy: advancing the treatment of ALL with immuno-oncology therapy

EHA Library, R Foà, 337322

Welcome and introduction

EHA Library, R Foà, 337323

Treatment of first relapse in childhood BCP-ALL

EHA Library, F Locatelli, 337324

Consolidation therapy for adult ALL: targeting minimal residual disease

EHA Library, N Gökbuget, 337325

Evolving approaches to treating early ITP

EHA Library, V McDonald, 337326

Putting theory into practice: case-based discussions around early ITP

EHA Library, V McDonald, 337327

AML treatment choices: key data and perspectives

EHA Library, MT Voso, 337328

Panel discussion and closing remarks

EHA Library, F Cervantes, 337329

Introduction to MF treatment and management

EHA Library, F Cervantes, 337330

The evolution of MF treatment - how I manage MF today

EHA Library, J Mascarenhas, 337331

Preparing for the future of MF management

EHA Library, A Reiter, 337332

How I manage AML in the era of novel treatments, plus panel discussion

EHA Library, E Stein, 337333

Interactive panel discussion and Q&A

EHA Library, A Davies, 337334

Where are we now with the management of follicular lymphoma?

EHA Library, A Davies, 337335

New challenges in the evolving follicular lymphoma treatment landscape

EHA Library, K Hübel, 337336

Case discussion: What can we do to optimise initial therapy in follicular lymphoma?

EHA Library, M Caballero, 337337

Assessment of Measurable Residual Disease (MRD) Status for the Management of Patients with Acute Lymphoblastic Leukemia (ALL).

EHA Library, E Jabbour, 337376

Monitoring Measurable Residual Disease (MRD) for Clinical Decision-Making in Acute Lymphoblastic Leukemia (ALL)

EHA Library, L Muffly, 337377

The Relevance of TCR Sequencing-Based Determination of the Cellular Immune Response in SARS-CoV-2 Infection

EHA Library, G Tonon, 337378

Panel Discussion

EHA Library, G Tonon, 337379